These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22863010)

  • 1. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.
    Wen Q; Goldenson B; Silver SJ; Schenone M; Dancik V; Huang Z; Wang LZ; Lewis TA; An WF; Li X; Bray MA; Thiollier C; Diebold L; Gilles L; Vokes MS; Moore CB; Bliss-Moreau M; Verplank L; Tolliday NJ; Mishra R; Vemula S; Shi J; Wei L; Kapur R; Lopez CK; Gerby B; Ballerini P; Pflumio F; Gilliland DG; Goldberg L; Birger Y; Izraeli S; Gamis AS; Smith FO; Woods WG; Taub J; Scherer CA; Bradner JE; Goh BC; Mercher T; Carpenter AE; Gould RJ; Clemons PA; Carr SA; Root DE; Schreiber SL; Stern AM; Crispino JD
    Cell; 2012 Aug; 150(3):575-89. PubMed ID: 22863010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasudil promotes polyploidization of megakaryoblasts in an acute megakaryocyte leukemia model.
    He B; Wang C; Niu J; Wang F; Zhang Y; Gao Y; Yang Q
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3101-3110. PubMed ID: 37162543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia.
    Krause DS; Crispino JD
    Clin Cancer Res; 2013 Nov; 19(22):6084-8. PubMed ID: 23963861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.
    Thiollier C; Lopez CK; Gerby B; Ignacimouttou C; Poglio S; Duffourd Y; Guégan J; Rivera-Munoz P; Bluteau O; Mabialah V; Diop M; Wen Q; Petit A; Bauchet AL; Reinhardt D; Bornhauser B; Gautheret D; Lecluse Y; Landman-Parker J; Radford I; Vainchenker W; Dastugue N; de Botton S; Dessen P; Bourquin JP; Crispino JD; Ballerini P; Bernard OA; Pflumio F; Mercher T
    J Exp Med; 2012 Oct; 209(11):2017-31. PubMed ID: 23045605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blocking PAK1 kinase activity promotes the differentiation of acute megakaryocytic leukemia cells and induces their apoptosis].
    Wang SJ; Wang CQ; Hu XT; Yu XR; Fu CL
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):499-505. PubMed ID: 35968594
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.
    Wen QJ; Yang Q; Goldenson B; Malinge S; Lasho T; Schneider RK; Breyfogle LJ; Schultz R; Gilles L; Koppikar P; Abdel-Wahab O; Pardanani A; Stein B; Gurbuxani S; Mullally A; Levine RL; Tefferi A; Crispino JD
    Nat Med; 2015 Dec; 21(12):1473-80. PubMed ID: 26569382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical and functional interactions between mitotic kinases during polyploidization and megakaryocytic differentiation.
    Huang X; Ruan Q; Fang Y; Traganos F; Darzynkiewicz Z; Dai W
    Cell Cycle; 2004 Jul; 3(7):946-51. PubMed ID: 15190214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of an AIM-1 kinase couples with megakaryocytic polyploidization of human hematopoietic cells.
    Kawasaki A; Matsumura I; Miyagawa Ji ; Ezoe S; Tanaka H; Terada Y; Tatsuka M; Machii T; Miyazaki H; Furukawa Y; Kanakura Y
    J Cell Biol; 2001 Jan; 152(2):275-87. PubMed ID: 11266445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BMP2K dysregulation promotes abnormal megakaryopoiesis in acute megakaryoblastic leukemia.
    Wang M; Zhang T; Zhang X; Jiang Z; Peng M; Huang Z
    Cell Biosci; 2020; 10():57. PubMed ID: 32322386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional reprogramming of polyploidization in megakaryocytes.
    Trakala M; Rodríguez-Acebes S; Maroto M; Symonds CE; Santamaría D; Ortega S; Barbacid M; Méndez J; Malumbres M
    Dev Cell; 2015 Jan; 32(2):155-67. PubMed ID: 25625205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
    Mohan P; Castellsague J; Jiang J; Allen K; Chen H; Nemirovsky O; Spyra M; Hu K; Kluwe L; Pujana MA; Villanueva A; Mautner VF; Keats JJ; Dunn SE; Lazaro C; Maxwell CA
    Oncotarget; 2013 Jan; 4(1):80-93. PubMed ID: 23328114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant quantity and localization of Aurora-B/AIM-1 and survivin during megakaryocyte polyploidization and the consequences of Aurora-B/AIM-1-deregulated expression.
    Zhang Y; Nagata Y; Yu G; Nguyen HG; Jones MR; Toselli P; Jackson CW; Tatsuka M; Todokoro K; Ravid K
    Blood; 2004 May; 103(10):3717-26. PubMed ID: 14751927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
    Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
    Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cyclin-dependent kinases 4/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia.
    Qi K; Hu X; Yu X; Cheng H; Wang C; Wang S; Wang Y; Li Y; Cao J; Pan B; Wu Q; Qiao J; Zeng L; Li Z; Xu K; Fu C
    Leuk Res; 2022 Sep; 120():106920. PubMed ID: 35872339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
    Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
    Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
    Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS
    Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
    Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [SP600125-induced polyploidization of megakaryocytic leukemia cell lines by ribosomal protein S6 kinase 1 depends on the degree of cell differentiation].
    Wang L; Yang J; Li C; Xing S; Yu Y; Liu S; Zhao S; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Oct; 32(10):1336-1341. PubMed ID: 27667458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation.
    Goldenson B; Kirsammer G; Stankiewicz MJ; Wen QJ; Crispino JD
    Blood; 2015 Mar; 125(13):2141-50. PubMed ID: 25670627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.